Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment JERSEY CITY, NJ, USA I April 01, 2025 I Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (Nasdaq: BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE ™ , a biosimilar to ACTEMRA ® , for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, wa

– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM –– Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function –– EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BO

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). Tolerability & Disease Control Rate: Shows potential superiority over current first- and second-line therapies. Unmet Medical Need: Enrolled patients with refractory or recurrent disease who had no remaining treatment options. TAIPEI and SAN DIEGO, April

N-acetylcysteine (NAC) shows promise to treat hereditary cystatin C amyloid angiopathy (HCCAA) HCCAA – a subtype of cerebral amyloid angiopathy (CAA) – is an ultra-rare Icelandic amyloid disease due to a mutation in the CST3 gene encoding for the protease inhibitor, cystatin C. HCCAA causes cerebral hemorrhages in asymptomatic carriers of the L68Q variant due to amyloid aggregation with precipitation in brain vessels and tissue. Findings could guide the development of preventative therapies for

Denosumab marks Accord's sixth biosimilar approval in Europe. The CHMP has issued a positive opinion for Denosumab, to be marketed as Osvyrti® and Jubereq®. Osvyrti® is Accord's second osteoporosis biosimilar, following Sondelbay®. The CHMP's endorsement paves the way for market authorization, with Accord set to launch Denosumab following patent expiry in November 2025 of the brand originator Prolia and Xgeva (Amgen denosumab brands). LONDON, April 2, 2025 /PRNewswire/ -- Accord Healthcare Limit

Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, April 2, 2025 /PRNewswire/ -- Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is enterin

EG 427 adds €27M series B for neurogenic bladder program BioWorld by Nuala Moran (subscriber only) Link to article

EG 427, a biotechnology company developing pinpoint gene therapy, today announced the closing of a €12 million Series A round. The round was led by David Lamond in association with San Francisco based large family offices. The financing will be used to move the company’s leading vector construct forward to clinical trials in neurogenic bladder. EG 427 focuses on creating a step-change in the gene therapy field by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and in particul

Philippe Chambon, PDG d'EG 427, était l'invité de Laure Closier dans French Tech, ce jeudi 27 février. Il a présenté des solutions à l'incontinence urinaire par le biais de thérapies géniques, qui ont permis de traiter un patient dans le cadre d'une étude clinique, dans Good Morning Business. Link to the replay

Home About us Technology Pipeline Clinical trials News Careers Contact us Home About us Technology Pipeline Clinical trials News Careers Contact us Issued European and Japanese patents cover herpes simplex virus (HSV) vectors selectively inhibiting subtype of sensory neurons Related initial therapeutic indications encompass multiple bladder conditions with a first focus on neurogenic detrusor overactivity Read full press release in English or in French read more > read more > read more > read mo